Supporting decisions for older adults with AML and their caregivers
Part of Blood & lymphatic, Cancer clinical trials.
This study helps older adults with newly diagnosed acute myeloid leukemia (AML) and their caregivers make informed decisions about treatment. You and a caregiver (like a family member or friend) will get extra support to talk through your options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older
- You have been diagnosed with acute myeloid leukemia (including related types like myeloid sarcoma)
- You have not started cancer treatment yet (except for medicine to safely lower high white blood cell counts or spinal chemotherapy)
- You can speak English or Spanish
- Your cancer doctor is willing to be part of the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a program that adds extra aging-related support to standard care for older adults with acute myeloid leukemia (AML) starting a type of treatment called venetoclax-based therapy. The goal is to see if this extra support improves quality of life and well-being.
This study tests a specialized (targeted) palliative care program versus usual oncology care for people hospitalized with high-risk acute myeloid leukemia (AML). The goal is to see if this palliative approach improves comfort, support, and care planning during intensive treatment.
This study uses a geriatric assessment to choose the best treatment for people aged 60 and older with acute myeloid leukemia (AML). The goal is to tailor therapy based on your overall health and function.
This study looks at whether geriatric (age-related health) evaluations help doctors choose better treatment for newly diagnosed AML (a type of leukemia). It may help translate older adults’ needs into a clearer, safer treatment plan.
This study tests an approach to help people with certain blood cancers and their main caregiver plan ahead and communicate more clearly about end-of-life care. It may help patients feel more supported and better prepared for difficult decisions.
This study follows people aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are receiving strong chemotherapy. It aims to learn more about their health outcomes and better understand the disease in this age group.
Hear when a new Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.